These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

192 related articles for article (PubMed ID: 31313097)

  • 1. Assessment of Risk of Disease Progression in Pulmonary Arterial Hypertension: Insights from an International Survey of Clinical Practice.
    Simons JE; Mann EB; Pierozynski A
    Adv Ther; 2019 Sep; 36(9):2351-2363. PubMed ID: 31313097
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Performance of DETECT Pulmonary Arterial Hypertension Algorithm According to the Hemodynamic Definition of Pulmonary Arterial Hypertension in the 2022 European Society of Cardiology and the European Respiratory Society Guidelines.
    Distler O; Bonderman D; Coghlan JG; Denton CP; Grünig E; Khanna D; McLaughlin VV; Müller-Ladner U; Pope JE; Vonk MC; Di Scala L; Lemarie JC; Perchenet L; Hachulla É
    Arthritis Rheumatol; 2024 May; 76(5):777-782. PubMed ID: 38146100
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Risk assessment in patients with functional class II pulmonary arterial hypertension: Comparison of physician gestalt with ESC/ERS and the REVEAL 2.0 risk score.
    Sahay S; Tonelli AR; Selej M; Watson Z; Benza RL
    PLoS One; 2020; 15(11):e0241504. PubMed ID: 33175857
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Screening for pulmonary arterial hypertension in patients with systemic sclerosis in the era of new pulmonary arterial hypertension definitions.
    Erdogan M; Kilickiran Avci B; Ebren C; Ersoy Y; Ongen Z; Ongen G; Hamuryudan V; Hatemi G
    Clin Exp Rheumatol; 2024 Aug; 42(8):1590-1597. PubMed ID: 38489342
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Folic acid supplementation and malaria susceptibility and severity among people taking antifolate antimalarial drugs in endemic areas.
    Crider K; Williams J; Qi YP; Gutman J; Yeung L; Mai C; Finkelstain J; Mehta S; Pons-Duran C; Menéndez C; Moraleda C; Rogers L; Daniels K; Green P
    Cochrane Database Syst Rev; 2022 Feb; 2(2022):. PubMed ID: 36321557
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Single-center prognostic validation of the risk assessment of the 2015 ESC/ERS guidelines in patients with pulmonary arterial hypertension in Japan.
    Imai R; Adachi S; Yoshida M; Shimokata S; Nakano Y; Okumura N; Murohara T; Kondo T
    Can J Physiol Pharmacol; 2020 Sep; 98(9):653-658. PubMed ID: 32924564
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Predicting Survival in Patients With Pulmonary Arterial Hypertension: The REVEAL Risk Score Calculator 2.0 and Comparison With ESC/ERS-Based Risk Assessment Strategies.
    Benza RL; Gomberg-Maitland M; Elliott CG; Farber HW; Foreman AJ; Frost AE; McGoon MD; Pasta DJ; Selej M; Burger CD; Frantz RP
    Chest; 2019 Aug; 156(2):323-337. PubMed ID: 30772387
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A pragmatic approach to risk assessment in pulmonary arterial hypertension using the 2015 European Society of Cardiology/European Respiratory Society guidelines.
    Dardi F; Manes A; Guarino D; Zuffa E; De Lorenzis A; Magnani I; Rotunno M; Ballerini A; Lo Russo GV; Nardi E; Galiè N; Palazzini M
    Open Heart; 2021 Oct; 8(2):. PubMed ID: 34667092
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Four-Strata Risk Assessment in Patients with Pulmonary Arterial Hypertension Treated with Selexipag in Real-World Settings (EXPOSURE Study).
    Lange TJ; Escribano-Subias P; Muller A; Fernandes CC; Fontana M; Remenova T; Söderberg S; Gaine S
    Adv Ther; 2024 Sep; 41(9):3645-3663. PubMed ID: 39083197
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Risk stratification, prognosis, and survival in a pulmonary arterial hypertension cohort in Latin America. A multicenter study.
    Diez M; Cáneva J; Diez A; Perna ER; Aimone D; Bosio M; Márquez LL; Brasca DG; Vulcano N; Daghero F; Burgos LM; Favaloro L; Escalante JP; Coronel ML; Fernández A; Chávez Á; Secco L;
    Respir Med Res; 2023 Jun; 83():100945. PubMed ID: 36563553
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Incorporation of renal function in mortality risk assessment for pulmonary arterial hypertension.
    Zelt JGE; Hossain A; Sun LY; Mehta S; Chandy G; Davies RA; Contreras-Dominguez V; Dunne R; Doyle-Cox C; Wells G; Stewart DJ; Mielniczuk LM
    J Heart Lung Transplant; 2020 Jul; 39(7):675-685. PubMed ID: 32336606
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Association of N-Terminal Pro Brain Natriuretic Peptide and Long-Term Outcome in Patients With Pulmonary Arterial Hypertension.
    Chin KM; Rubin LJ; Channick R; Di Scala L; Gaine S; Galiè N; Ghofrani HA; Hoeper MM; Lang IM; McLaughlin VV; Preiss R; Simonneau G; Sitbon O; Tapson VF
    Circulation; 2019 May; 139(21):2440-2450. PubMed ID: 30982349
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Assessment of Knowledge, Attitude, and Practice Patterns in Pulmonary Arterial Hypertension among Cardiologists and Pulmonologists: Evidence from Turkey.
    Günaydın FE; Belen E; Altın S; Demir AU; Güven G; Durmuş G
    Medicina (Kaunas); 2023 Oct; 59(10):. PubMed ID: 37893587
    [No Abstract]   [Full Text] [Related]  

  • 14. [Risk stratification in pulmonary arterial hypertension - implementation of an internet-based risk calculator to guide treatment].
    Ahmed A; Ahmed S; Rådegran G
    Lakartidningen; 2023 Oct; 120():. PubMed ID: 37870224
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The diagnostic journey of pulmonary arterial hypertension patients: results from a multinational real-world survey.
    Small M; Perchenet L; Bennett A; Linder J
    Ther Adv Respir Dis; 2024; 18():17534666231218886. PubMed ID: 38357903
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Mixed Venous Oxygen Saturation Is a Better Prognosticator Than Cardiac Index in Pulmonary Arterial Hypertension.
    Khirfan G; Almoushref A; Naal T; Abuhalimeh B; Dweik RA; Heresi GA; Tonelli AR
    Chest; 2020 Dec; 158(6):2546-2555. PubMed ID: 32629034
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Simplified risk stratification for pulmonary arterial hypertension associated with connective tissue disease.
    Li X; Sun X; Huang Y; Wang Y; Yang X; Wang J; Zhang N; Gu L; Zhang M; Wang Q
    Clin Rheumatol; 2019 Dec; 38(12):3619-3626. PubMed ID: 31385084
    [TBL] [Abstract][Full Text] [Related]  

  • 18. European Society of Cardiology quality indicators for the care and outcomes of adults with pulmonary arterial hypertension. Developed in collaboration with the Heart Failure Association of the European Society of Cardiology.
    Aktaa S; Gale CP; Brida M; Giannakoulas G; Kovacs G; Adir Y; Benza RL; Böhm M; Coats A; D'Alto M; Escribano-Subias P; Ferrari P; Galiè N; Gibbs JSR; Gin-Sing W; Hoeper MM; Humbert M; Lang IM; Maron BA; Meszaros G; Vonk Noordegraaf A; Price LC; Pepke-Zaba J; Rådegran G; Reis A; Sitbon O; Torbicki A; Ulrich S; Rosenkranz S; Delcroix M
    Eur J Heart Fail; 2023 Apr; 25(4):469-477. PubMed ID: 36924171
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Guidelines for the Treatment of Pulmonary Arterial Hypertension.
    Vazquez ZGS; Klinger JR
    Lung; 2020 Aug; 198(4):581-596. PubMed ID: 32671468
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Treatment Patterns and Associated Health Care Costs Before and After Treatment Initiation Among Pulmonary Arterial Hypertension Patients in the United States.
    Burger CD; Ozbay AB; Lazarus HM; Riehle E; Montejano LB; Lenhart G; White RJ
    J Manag Care Spec Pharm; 2018 Aug; 24(8):834-842. PubMed ID: 29436260
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.